Accelerate Diagnostics Price to Free Cash Flow Ratio 2010-2024 | AXDX

Accelerate Diagnostics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Accelerate Diagnostics Price to Free Cash Flow Ratio 2010-2024 | AXDX

Accelerate Diagnostics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.2B
Intuitive Surgical (ISRG)$171.7B
Alcon (ALC)$47.9B
IQVIA Holdings (IQV)$43.7B
IDEXX Laboratories (IDXX)$42.2B
Edwards Lifesciences (EW)$40.5B
DexCom (DXCM)$27.6B
STERIS (STE)$23.8B
SONOVA HOLDING (SONVY)$21.2B
Waters (WAT)$19.5B
Hologic (HOLX)$19B
Sysmex ADR (SSMXY)$12.6B
Fresenius Medical Care AG KGaA (FMS)$12.3B
Teleflex (TFX)$11.4B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.3B
Glaukos (GKOS)$6.7B
Masimo (MASI)$6.1B
TransMedics (TMDX)$5.2B
Integer Holdings (ITGR)$4.2B
PROCEPT BioRobotics (PRCT)$4.1B
Tandem Diabetes Care (TNDM)$2.8B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.6B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.5B
Nihon Kohden (NHNKY)$2.5B
RxSight (RXST)$2.1B
Integra LifeSciences Holdings (IART)$1.3B
Pulse Biosciences (PLSE)$1.2B